PALATINE, Ill., July 21, 2008 (PRIME NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) today announced that it has filed with the United States Patent and Trademark Office (“USPTO”) a Request for Continued Examination relating to the Notice of Allowance received in June, 2008 for its non-provisional patent application 11/716,122 titled “Methods and Compositions for Deterring Abuse of Opioid Containing Dosage Forms” (the “122 Application”).
